O	0	5	Phase
O	6	8	II
O	9	14	study
O	15	17	of
B-intervention	18	27	metformin
O	28	31	for
O	32	41	reduction
O	42	44	of
O	45	52	obesity
O	52	53	-
O	53	63	associated
O	64	70	breast
O	71	77	cancer
O	78	82	risk
O	82	83	:
O	84	85	a
O	86	96	randomized
O	97	107	controlled
O	108	113	trial
O	114	122	protocol
O	122	123	.

O	124	127	Two
O	127	128	-
O	128	134	thirds
O	135	137	of
B-location	138	139	U
I-location	139	140	.
I-location	140	141	S
I-location	141	142	.
O	143	148	adult
O	149	154	women
O	155	158	are
O	159	169	overweight
O	170	172	or
O	173	178	obese
O	178	179	.

O	180	184	High
O	185	189	body
O	190	194	mass
O	195	200	index
O	201	202	(
O	202	205	BMI
O	205	206	)
O	207	210	and
O	211	216	adult
O	217	223	weight
O	224	228	gain
O	229	232	are
O	233	237	risk
O	238	245	factors
O	246	249	for
O	250	251	a
O	252	258	number
O	259	261	of
O	262	269	chronic
O	270	278	diseases
O	278	279	,
O	280	289	including
O	290	304	postmenopausal
O	305	311	breast
O	312	318	cancer
O	318	319	.

O	320	323	The
O	324	330	higher
O	331	345	postmenopausal
O	346	352	breast
O	353	359	cancer
O	360	364	risk
O	365	367	in
O	368	373	women
O	374	378	with
O	379	387	elevated
O	388	391	BMI
O	392	394	is
O	395	401	likely
O	402	404	to
O	405	407	be
O	408	420	attributable
O	421	423	to
O	424	431	related
O	432	441	metabolic
O	442	454	disturbances
O	455	464	including
O	465	472	altered
O	473	484	circulating
O	485	488	sex
O	489	496	steroid
O	497	505	hormones
O	506	509	and
O	510	520	adipokines
O	520	521	,
O	522	530	elevated
O	531	534	pro
O	534	535	-
O	535	547	inflammatory
O	548	557	cytokines
O	557	558	,
O	559	562	and
O	563	570	insulin
O	571	581	resistance
O	581	582	.

O	583	592	Metformin
O	593	595	is
O	596	597	a
O	598	604	widely
O	605	609	used
O	610	622	antidiabetic
O	623	627	drug
O	628	632	that
O	633	636	has
O	637	649	demonstrated
O	650	659	favorable
O	660	667	effects
O	668	670	on
O	671	680	metabolic
O	681	693	disturbances
O	694	697	and
O	698	700	as
O	701	705	such
O	706	709	may
O	710	714	lead
O	715	717	to
O	718	723	lower
O	724	730	breast
O	731	737	cancer
O	738	742	risk
O	743	745	in
O	746	751	obese
O	752	757	women
O	757	758	.

O	759	766	Further
O	766	767	,
O	768	771	the
O	772	776	anti
O	776	777	-
O	777	790	proliferative
O	791	798	effects
O	799	801	of
O	802	811	metformin
O	812	819	suggest
O	820	822	it
O	823	826	may
O	827	835	decrease
O	836	842	breast
O	843	850	density
O	850	851	,
O	852	854	an
O	855	863	accepted
O	864	873	biomarker
O	874	876	of
O	877	883	breast
O	884	890	cancer
O	891	895	risk
O	895	896	.

O	897	901	This
O	902	904	is
O	905	906	a
O	907	912	Phase
O	913	915	II
O	916	926	randomized
O	926	927	,
O	928	934	double
O	934	935	-
O	935	940	blind
O	940	941	,
O	942	949	placebo
O	949	950	-
O	950	960	controlled
O	961	966	trial
O	967	969	of
O	970	979	metformin
O	980	982	in
B-eligibility	983	993	overweight
I-eligibility	993	994	/
I-eligibility	994	999	obese
I-eligibility	1000	1013	premenopausal
I-eligibility	1014	1019	women
I-eligibility	1020	1023	who
I-eligibility	1024	1028	have
I-eligibility	1029	1037	elements
I-eligibility	1038	1040	of
I-eligibility	1041	1050	metabolic
I-eligibility	1051	1059	syndrome
O	1059	1060	.

O	1061	1069	Eligible
O	1070	1082	participants
O	1083	1087	will
O	1088	1090	be
O	1091	1101	randomized
O	1102	1104	to
O	1105	1112	receive
O	1113	1122	metformin
O	1123	1126	850
O	1127	1129	mg
O	1130	1133	BID
O	1134	1135	(
O	1135	1136	n
O	1137	1138	=
B-intervention-participants	1139	1141	75
O	1141	1142	)
O	1143	1145	or
B-control	1146	1153	placebo
O	1154	1155	(
O	1155	1156	n
O	1157	1158	=
B-control-participants	1159	1161	75
O	1161	1162	)
O	1163	1166	for
O	1167	1169	12
O	1170	1176	months
O	1176	1177	.

O	1178	1181	The
O	1182	1189	primary
O	1190	1198	endpoint
O	1199	1201	is
B-outcome-Measure	1202	1208	change
I-outcome-Measure	1209	1211	in
I-outcome-Measure	1212	1218	breast
I-outcome-Measure	1219	1226	density
O	1226	1227	,
O	1228	1233	based
O	1234	1236	on
O	1237	1245	magnetic
O	1246	1255	resonance
O	1256	1263	imaging
O	1264	1265	(
O	1265	1268	MRI
O	1268	1269	)
O	1270	1278	acquired
O	1279	1282	fat
O	1282	1283	-
O	1283	1288	water
O	1289	1297	features
O	1297	1298	.

O	1299	1308	Secondary
O	1309	1317	outcomes
O	1318	1325	include
B-outcome-Measure	1326	1333	changes
I-outcome-Measure	1334	1336	in
I-outcome-Measure	1337	1342	serum
I-outcome-Measure	1343	1350	insulin
I-outcome-Measure	1351	1357	levels
O	1357	1358	,
B-outcome-Measure	1359	1364	serum
I-outcome-Measure	1365	1372	insulin
I-outcome-Measure	1372	1373	-
I-outcome-Measure	1373	1377	like
I-outcome-Measure	1378	1384	growth
I-outcome-Measure	1385	1391	factor
I-outcome-Measure	1392	1393	(
I-outcome-Measure	1393	1396	IGF
I-outcome-Measure	1396	1397	)
I-outcome-Measure	1397	1398	-
I-outcome-Measure	1398	1399	1
I-outcome-Measure	1400	1402	to
I-outcome-Measure	1403	1410	insulin
I-outcome-Measure	1410	1411	-
I-outcome-Measure	1411	1415	like
I-outcome-Measure	1416	1422	growth
I-outcome-Measure	1423	1429	factor
I-outcome-Measure	1430	1437	binding
I-outcome-Measure	1438	1445	protein
I-outcome-Measure	1446	1447	(
I-outcome-Measure	1447	1452	IGFBP
I-outcome-Measure	1452	1453	)
I-outcome-Measure	1453	1454	-
I-outcome-Measure	1454	1455	3
I-outcome-Measure	1456	1461	ratio
O	1461	1462	,
B-outcome-Measure	1463	1468	serum
I-outcome-Measure	1469	1472	IGF
I-outcome-Measure	1472	1473	-
I-outcome-Measure	1473	1474	2
I-outcome-Measure	1475	1481	levels
O	1481	1482	,
B-outcome-Measure	1483	1488	serum
I-outcome-Measure	1489	1501	testosterone
I-outcome-Measure	1502	1508	levels
O	1508	1509	,
B-outcome-Measure	1510	1515	serum
I-outcome-Measure	1516	1522	leptin
I-outcome-Measure	1523	1525	to
I-outcome-Measure	1526	1537	adiponectin
I-outcome-Measure	1538	1543	ratio
O	1543	1544	,
B-outcome-Measure	1545	1549	body
I-outcome-Measure	1550	1556	weight
O	1556	1557	,
O	1558	1561	and
B-outcome-Measure	1562	1567	waist
I-outcome-Measure	1568	1581	circumference
O	1581	1582	.

O	1583	1594	Exploratory
O	1595	1603	outcomes
O	1604	1611	include
B-outcome-Measure	1612	1619	changes
I-outcome-Measure	1620	1622	in
I-outcome-Measure	1623	1634	metabolomic
I-outcome-Measure	1635	1643	profiles
I-outcome-Measure	1644	1646	in
I-outcome-Measure	1647	1653	plasma
I-outcome-Measure	1654	1657	and
I-outcome-Measure	1658	1664	nipple
I-outcome-Measure	1665	1673	aspirate
I-outcome-Measure	1674	1679	fluid
O	1679	1680	.

O	1681	1688	Changes
O	1689	1691	in
O	1692	1698	tissue
O	1699	1711	architecture
O	1712	1714	as
O	1715	1719	well
O	1720	1722	as
O	1723	1731	cellular
O	1732	1735	and
O	1736	1745	molecular
O	1746	1753	targets
O	1754	1756	in
O	1757	1763	breast
O	1764	1770	tissue
O	1771	1780	collected
O	1781	1783	in
O	1784	1785	a
O	1786	1794	subgroup
O	1795	1797	of
O	1798	1810	participants
O	1811	1815	will
O	1816	1820	also
O	1821	1823	be
O	1824	1832	explored
O	1832	1833	.

O	1834	1837	The
O	1838	1843	study
O	1844	1848	will
O	1849	1857	evaluate
O	1858	1865	whether
O	1866	1875	metformin
O	1876	1879	can
O	1880	1886	result
O	1887	1889	in
O	1890	1899	favorable
O	1900	1907	changes
O	1908	1910	in
O	1911	1917	breast
O	1918	1925	density
O	1925	1926	,
O	1927	1933	select
O	1934	1942	proteins
O	1943	1946	and
O	1947	1955	hormones
O	1955	1956	,
O	1957	1965	products
O	1966	1968	of
O	1969	1973	body
O	1974	1984	metabolism
O	1984	1985	,
O	1986	1989	and
O	1990	1994	body
O	1995	2001	weight
O	2002	2005	and
O	2006	2017	composition
O	2017	2018	.

O	2019	2022	The
O	2023	2028	study
O	2029	2035	should
O	2036	2040	help
O	2041	2050	determine
O	2051	2054	the
O	2055	2064	potential
O	2065	2071	breast
O	2072	2078	cancer
O	2079	2089	preventive
O	2090	2098	activity
O	2099	2101	of
O	2102	2111	metformin
O	2112	2114	in
O	2115	2116	a
O	2117	2124	growing
O	2125	2135	population
O	2136	2138	at
O	2139	2143	risk
O	2144	2147	for
O	2148	2156	multiple
O	2157	2165	diseases
O	2165	2166	.

O	2167	2181	ClinicalTrials
O	2181	2182	.
O	2182	2185	gov
O	2186	2196	Identifier
O	2196	2197	:
O	2198	2209	NCT02028221
O	2210	2211	.

O	2212	2222	Registered
O	2223	2225	on
O	2226	2233	January
O	2234	2235	2
O	2235	2236	,
O	2237	2241	2014
O	2241	2242	.

O	2243	2248	Grant
O	2249	2250	#
O	2250	2251	:
O	2252	2264	1R01CA172444
O	2264	2265	-
O	2265	2269	01A1
O	2270	2277	awarded
O	2278	2280	on
O	2281	2285	Sept
O	2286	2288	11
O	2288	2289	,
O	2290	2294	2013
O	2294	2295	.
